Home

Kymera Therapeutics, Inc. - Common Stock (KYMR)

44.26
+0.68 (1.56%)
NASDAQ · Last Trade: Jun 4th, 9:56 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close43.58
Open43.73
Bid44.35
Ask45.50
Day's Range42.83 - 45.45
52 Week Range19.45 - 53.27
Volume1,144,672
Market Cap2.45B
PE Ratio (TTM)-14.85
EPS (TTM)-3.0
Dividend & YieldN/A (N/A)
1 Month Average Volume573,310

Chart

About Kymera Therapeutics, Inc. - Common Stock (KYMR)

Kymera Therapeutics Inc is a biotechnology company focused on developing innovative therapeutics that harness the power of targeted protein degradation to treat a range of diseases, including cancer and autoimmune disorders. By utilizing its proprietary technology platform, the company aims to design and create small molecules that can selectively degrade specific proteins, thereby offering a novel approach to addressing previously difficult-to-target biological pathways. Kymera's pipeline includes a variety of drug candidates that advance the understanding of protein function and the potential for transformative treatments, positioning the company at the forefront of the next generation of precision medicine. Read More

News & Press Releases

Signet Posts Upbeat Earnings, Joins Ferguson Enterprises, Dollar General And Other Big Stocks Moving Higher On Tuesdaybenzinga.com
Via Benzinga · June 3, 2025
Disney To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesdaybenzinga.com
Via Benzinga · June 3, 2025
What 6 Analyst Ratings Have To Say About Kymera Therapeuticsbenzinga.com
Via Benzinga · June 3, 2025
Kymera Therapeutics Soars After Multiple Analyst Upgrades; Retail Sentiment Turns Extremely Bullishstocktwits.com
Morgan Stanley, BofA, and Citi upgraded the stock, citing strong safety, biomarker, and degradation data for its STAT6 degrader KT-621.
Via Stocktwits · June 2, 2025
What's Next: Kymera Therapeutics's Earnings Previewbenzinga.com
Via Benzinga · May 8, 2025
Demystifying Kymera Therapeutics: Insights From 6 Analyst Reviewsbenzinga.com
Via Benzinga · February 28, 2025
Earnings Scheduled For February 27, 2025benzinga.com
Via Benzinga · February 27, 2025
The Latest Analyst Ratings For Kymera Therapeuticsbenzinga.com
Via Benzinga · November 1, 2024
Here are the top movers in Monday's session.chartmill.com
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · June 2, 2025
Which stocks are experiencing notable movement on Monday?chartmill.com
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · June 2, 2025
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · June 2, 2025
Preview: Kymera Therapeutics's Earningsbenzinga.com
Via Benzinga · October 30, 2024
Insights Ahead: Kymera Therapeutics's Quarterly Earningsbenzinga.com
Via Benzinga · October 30, 2024
The Analyst Landscape: 7 Takes On Kymera Therapeuticsbenzinga.com
Via Benzinga · September 27, 2024
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeuticsbenzinga.com
Via Benzinga · September 9, 2024
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Responsebenzinga.com
Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials planned through early 2026.
Via Benzinga · June 2, 2025
These stocks that are showing activity before the opening bell on Monday.chartmill.com
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.
Via Chartmill · June 2, 2025
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · June 2, 2025
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · May 30, 2025
Friday's after hours session: top gainers and loserschartmill.com
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via Chartmill · May 30, 2025
The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Expertsbenzinga.com
Via Benzinga · May 12, 2025
Earnings Scheduled For May 9, 2025benzinga.com
Via Benzinga · May 9, 2025
Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?benzinga.com
Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Kymera Therapeutics.
Via Benzinga · April 27, 2025
Why Kymera Therapeutics Stock Crushed it This Weekfool.com
Via The Motley Fool · April 25, 2025
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlightsbenzinga.com
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.
Via Benzinga · October 30, 2024